conference was audio recorded (audio recordings and accompanying slide shows are available on the CARG website at http://www. mycarg.org/home). Following the conference, the presentations were transcribed and reviewed by the principal investigators (A. Hurria, S. G. Mohile, W. Dale) to identify the main themes and the specific recommendations from this first conference. These recommendations were synthesized in collaboration with the advisory board and are summarized in this commentary.
Previous Research
What Is Known Conference panelists with a wide spectrum of expertise summarized the current level of evidence in geriatric oncology research. Table 1 highlights a sample of clinical trials that focused on older patients with cancer. Several themes that emerged centered on study design and the level of evidence in geriatric oncology (Table 2) . First, few clinical trials have been designed specifically for older adults with cancer. More commonly, evidence regarding the treatment of older adults emerges from studies that have enrolled patients of all ages. Notably, the number of older adults enrolled in standard clinical trials rarely reflects the proportion of older patients with the disease in the general population. Second, measures of functional or physiological age, which are routinely captured in geriatric assessment, are rarely included in study designs. Thus, it is difficult to know if the results of these studies can be extrapolated to the general geriatric oncology population.
Given that the majority of cancers are diagnosed in adults aged 65 years or older, a rationale for formulating high-quality studies in older adults with cancer was discussed. Many studies simply show a difference in treatment patterns between older and younger cancer patients without identifying the reasons for these differences. Also, many studies demonstrate that older adults enrolled in cancer clinical trials derive similar treatment-related benefits as younger adults, but the older adults are at increased risk for treatmentrelated toxicities. Furthermore, few studies have measured specific age-associated characteristics that identify older adults who are at highest risk for toxic effects and poor outcomes. Finally, although it is possible to perform high-quality clinical trials of fit older adults in the cooperative group setting, few studies focus on enrolling vulnerable and/or frail older adults and those older than 75 years.
Research Gaps
Older patients who are enrolled in clinical trials typically have a high performance status, very few comorbidities, no functional losses, and well-preserved organ function, thereby limiting the generalizability of the findings to the majority of older adults who have cancer. More trials that specifically target older adults are needed to address the physiological differences between older and younger patients, differences that can affect both cancer biology and response to therapy. There is also a need to enroll more older patients into ongoing clinical trials for patients of all ages, as well as to develop tailored trials for vulnerable older adults with underlying deficits identified by geriatric assessment tools. To assess less fit patients and safely enroll them in such trials, we need to know how to build the necessary infrastructure to support them. Ways to fill these gaps were discussed, and resulting recommendations follow.
Addressing the Existing Gaps

Gap 1: Clinical Measures Most Relevant to Older Adults Are Rarely Incorporated Into Oncology Clinical Trials
We presume, largely on the basis of traditional measures of performance status (such as the Karnofsky score), that older patients who are typically enrolled in clinical trials are more "fit," that is, not especially vulnerable to toxic side effects or poor outcomes. However, most oncology trial designs include few measures from geriatric assessment domains (eg, comorbidity, detailed functional status, cognition) (36) . Most patients who are aged 65 years or older when diagnosed with cancer have multiple comorbidities, functional losses, geriatric syndromes, and/or physical disabilities (36) . One study showed that these factors affect 74% of patients with breast cancer, 88% of patients with prostate cancer, and 86% of patients with colorectal cancer (37) . An Italian study found that geriatric assessment provides prognostic information in addition to standard performance assessment in older patients with cancer (38) . However, few studies measure these geriatric domains, despite the ability of such assessments to add important prognostic information (39) .
Standardized geriatric assessment tools can help determine a patient's eligibility for cancer trials, choice of treatment, and underlying vulnerability to treatment-related toxicities. Incorporating such an assessment would improve the design of clinical trials and allow entry criteria to be individualized beyond the use of age or performance status cutoffs. Comprehensive standardized assessments would also allow investigators to analyze how more vulnerable patients respond to therapy, which may help to further refine the risk factors that are most important to consider when making treatment decisions for older cancer patients or stratifying such patients for clinical trial enrollment.
A variety of geriatric assessment measures have recently been assessed for their ability to predict toxic effects of chemotherapy. For example, investigators from the CARG group developed a risk stratification schema for chemotherapy toxicities. Factors found to predict the risk of chemotherapy toxicities included age, tumor and treatment characteristics (ie, cancer type, receipt of standard treatment dose, and use of polychemotherapy), specific laboratory values (ie, lower hemoglobin level, worse creatinine clearance), and geriatric assessment variables (ie, any hearing impairment, a fall in the previous 6 months, difficulty in walking one block, need for assistance with taking medications, and decreased social activities) (40) . A scoring system based on these factors was developed to identify patients who are at low, intermediate, or high risk of chemotherapy toxicities. In addition, Extermann et al. (41) developed the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score, which predicts the likelihood of chemotherapy toxicity using measures such as albumin levels, blood pressure, the need for assistance with instrumental activities of daily living, reduced cognitive status, poor nutrition status, and abnormal performance status. However, additional research is needed to validate and generalize the use of these tools in older patients with different tumor types, receiving various treatment regimens, and in different care settings. Previous research has demonstrated that it is feasible to include a geriatric assessment in the cooperative group setting (42) . However, the technology needed to capture these geriatric assessment data must be identified and evaluated for use outside academic medical centers. Close collaboration between oncologists and geriatric oncologists or geriatricians is necessary when designing clinical trials that involve older adults to ensure that geriatric principles and assessments are considered in oncology trial design. More research needs to be done regarding the utility of geriatric assessments in various tumor types and when using therapies with different toxic effects, both for toxicity prediction and for more appropriately measuring outcomes in older adults. Table 2 outlines questions that a geriatric assessment would help to answer. Although mortality reduction is important for patients of all ages, for older patients, additional endpoints, such as the ability to live independently and with a high quality of life, may be equally (or more) important. Thus, the impact of cancer and its treatments on patients' abilities to maintain function and independence should be more thoroughly investigated. Such data could be used to facilitate treatment discussions with older patients, as well as to inform decision making for patients who are faced with different treatment options. Findings from such studies would also allow researchers to incorporate age-appropriate health outcomes into studies of older adults and help guide care for older patients.
The relationship between cancer treatments and mental health and/or cognitive changes is an important concern for older patients, yet most existing data are based on small sample sizes. Larger studies are needed to assess the incidence of depression, anxiety, and stress in older patients with cancer, as well as risk factors that predict how treatment will affect these conditions and vice versa. Information about these psychological symptoms could be collected by using "patient-reported" methods such as in-home technology (such as smart phones) and web-based surveys. Validated measures assessing cognitive changes during and after treatment are another area ripe for additional research. Consideration should be given to implementing studies in parallel with standard phase III trials to measure the impact of treatment on physical function, cognition, and quality of life in older study participants.
Gap 2: Biological and Physiological Markers of Aging Are Inconsistently Incorporated in Oncology Research
Aging brings biological changes in tumor characteristics, as well as potential physiological changes in the "host organism" (ie, the patient). In both men and women, parameters such as body weight, grip strength, and aerobic capacity decline with age, leading to frailty, increased disease susceptibility, reduced healing, and other conditions of vulnerability (43) . Aging is also marked by an increase in the circulating levels of several inflammatory factors, including the interleukins, C-reactive protein, and fibrinogen (44) . For example, increased plasma levels of interleukin 6 were found to predict mobility deficits and worsened activities of daily living in people aged 71 years or older (45) .
A biological link appears to exist between aging and cancer, and there are several age-associated molecular changes that contribute to carcinogenesis. In vitro and murine in vivo experiments suggest that a predisposition to cancer in older organisms could result from the combined effects of a high mutation load, poor epigenetic regulation, telomere dysfunction, and altered stromal milieu (46) . One specific example of a biological link between cancer and aging is the theory of antagonistic pleiotropy, the hypothesis that evolutionarily selected biological functions benefit younger individuals at the expense of older ones (47) . For example, cellular senescence is a defense mechanism against the unregulated cellular proliferation underlying carcinogenesis in younger individuals, whereas widespread senescence and the subsequent release of inflammatory factors possibly play a role in several diseases of older individuals, including cancer (48) . Another possible biological link between cancer and aging is the proliferation of dysfunctional telomeres in both older individuals and those individuals with cancer (49) . The reverse may also be true: it is possible that cancer and/or its treatments may lead to an acceleration of the aging process at the cellular level (50) . Further research is needed to elucidate the causal relationships behind the identified associations.
Chemotherapy toxicity may also be influenced by age-related alterations in the pharmacokinetics and pharmacodynamics of cancer therapy (Table 1) . For example, older adults with serum levels of creatinine in the "normal" range may in fact have a decreased glomerular filtration rate (51), which could influence chemotherapy toxicity. A small number of studies have examined changes in the toxicity of anticancer agents according to age. For example, a CALGB study of the chemotherapeutic agent paclitaxel assessed the pharmacokinetics and toxicities associated with the drug in three cohorts of older patients aged 55-65, 65-75, or older than 75 years and found that older patients cleared the drug more slowly than younger patients (52) . However, no statistically significant association between age and clinically important adverse events, including hospitalization for toxicity, the need for intravenous antibiotics, or neutropenic fever, was detected.
Filling Gap 2: Consistent Incorporation of Biological and Physiological Markers of Aging in Oncology Clinical Trials
To assess whether tumor biology changes substantially with age, as has been observed for cytogenetic abnormalities in acute myeloid leukemia (53), a wide range of tumor samples from patients of all ages should be collected and analyzed. The connection between inflammatory factors, aging, and cancer also needs to be clarified, and further research into the association between chronic inflammation and cancer development is needed. In preclinical studies involving model organisms, increased use of animals that are older and more vulnerable to disease is encouraged to simulate the biological status of typical older cancer patients. Similarly, treatment parameters such as body composition for weight-based treatments, pharmacokinetics and pharmacodynamics of therapeutics, and chemotherapy dosing based on organ function are necessary to improve treatment selection and dosing choices for older adults.
Gap 3: Too Few Studies Focus on Frail Older Adults or Those Aged 75 Years or Older
Although older age and frailty-a condition of increased vulnerability to disease and decline-are correlated (54), they are not identical. Some older adults are robust, not prone to develop diseases, and resistant to decline, whereas some older adults are most vulnerable to disease and decline. Unfortunately, there is a paucity of data on cancer treatments in either the frailest adults or those adults older than 75 years, primarily due to low enrollment of both groups in cancer clinical trials (Figure 1) . A review of NCI-funded studies found that whereas 3% of cancer patients aged 30-64 years were represented in trials, only 1.3% of those aged 65-74 years and 0.5% of those older than 75 years were represented (2) . One likely contributor to this age disparity in trial enrollment is the fact that frailer, older patients are rarely offered the opportunity to participate in trials. For example, half as many eligible women with breast cancer aged 65 years or older are offered a trial compared with women younger than 65 years (55, 56) . Reasons cited for not offering trial participation to older women include concerns about the number of comorbidities, perceived poor adherence to treatment, treatment toxicities, and straightforward exclusion by eligibility criteria. There is also often the erroneous perception that older patients are less accepting of trials, so they are not offered to these patients; however, when offered the opportunity, older patients are just as likely as younger patients to enroll in a clinical trial (55, 56) . Additionally, older patients are less likely to present for treatment at sites with access to clinical trials, such as NCIdesignated cancer centers (57) .
Filling Gap 3: More Studies That Focus on Frailer Older Adults and/or Those Aged 75 Years or Older
There is a need to develop clinical trials and observational studies that actively enroll this older, more vulnerable population as well as criteria to guide the development of more appropriate trials for these individuals. For less fit older patients who are excluded from standard clinical trials because of frailty, performance status, or comorbidity restrictions, specific trials for an alternative dosing or schedule or enhanced supportive care measures should be designed and conducted. The efficacy and toxicity of treatment approaches in these patients should also be evaluated. Extra safety considerations can be built into the trial design to offset toxicity, address it promptly if it occurs, and maximize safety for this vulnerable population. Rather than focusing primarily on mortality, future studies should include equally important outcomes, such as the efficacy of reduced chemotherapy doses on cancer control as well as the short-and long-term impacts of therapy on functional abilities, cognition, symptom control, and other comorbidities. Inclusion of such outcomes could greatly improve the treatment of older and frailer cancer patients, especially given the paucity of data on the treatment of these patients, who are typically ineligible for standard clinical trials. Another option is to include a "registry" study to capture the decision making and outcomes of patients who do not qualify for a standard clinical trial.
Gap 4: Clinical Trial Infrastructure Incompatibility With Geriatric Needs
Research is needed to assess the barriers to clinical trial enrollment of older adults and to identify programs or trial designs to overcome these barriers. Assessments of needs that are built into the screening process to identify enrollment and treatment barriersincluding lack of transportation, inability to get attention if sick, inability to complete daily activities, the need to serve as a caregiver for a dependent spouse, and financial barriers (eg, the cost of medications or for caregiver time)-are virtually never done. Oncology research staff rarely has specific training in these geriatrics issues. When caring for older cancer patients in the trial setting, additional time is not typically allotted to complete written informed consent documents, conduct geriatric assessments, or to manage potential toxicities. Additional infrastructure is rarely present to support participation in a trial for frail, older adults (ie, lowered examination tables, transportation assistance), or nearby housing if treatment or tests span several days.
Filling Gap 4: Incorporate Age-Associated Conditions of Older Adults Into Research Infrastructure
Better tailoring oncology care to meet the needs of older frail patients would almost surely increase enrollment of these patients Figure 1 . Percentage of robust (0 of 5 deficits), pre-frail (1-2 of 5 deficits), and frail (3 or more deficits) older adults in three age groups and the quality of the evidence regarding appropriate cancer treatments by age. Based on data from Fried et al. (54) .
in clinical trials. With the increased inclusion of older patients in medical research, facilities are more likely to make their clinical environments more convenient, such as providing wider lower examination tables and easier access to assistive devices. Sufficient time is also needed to complete geriatric assessments in clinical trials. Pilot studies are needed to quantify the impact of providing older adults with transportation to large centers on clinical trial enrollment and retention. In addition, developing and expanding community-based trials for older adults would eliminate the need for long distance travel to access clinical trials. Research nurses and data managers should receive specific training in the care of older adults. Data collection from remote locations can also be improved by incorporating advanced technology such as smart phones and tablet computers. Finally, home-monitoring programs that use visits by a nurse or social worker, telephone calls, or internet portals to support the well-being of older adults during cancer therapy are promising and must be explored further (58) .
In addition, more consistent and earlier collaboration between oncology and geriatrics researchers is essential. A multidisciplinary team should closely collaborate to design, implement, and execute clinical trials for older adults. Integrating geriatricians and other providers who have geriatric training and experience into an older patient's treatment plan could potentially improve adherence and help minimize the impact of toxicities, particularly if the patient is frailer or has other conditions; measuring the size of that potential benefit alone constitutes a promising research topic. Targeted assistance based on particular comorbidities or other existing conditions is also strongly advised; this is a situation in which multidisciplinary collaboration between oncologists, geriatricians, and others would be enormously beneficial. The inclusion of other health-care providers, including clinical psychologists, social workers, physician extenders, and physical and occupational therapists, especially those with geriatric training, is critical in treating older patients. In short, both multiand interdisciplinary teams that are led by oncologists and geriatricians are necessary to allow geriatric oncology research to progress.
Summary
Although the cancer community has made enormous strides in cancer treatment in general, several gaps in knowledge remain when it comes to research and treatment for older cancer patients. To address these gaps, future oncology research for older patients with cancer must include: 1) comprehensive clinical geriatric assessments, 2) improved biological assessments, 3) more trials specifically tailored for patients that are frail and older than 75 years, and 4) an enhanced research infrastructure that addresses the issues pertinent to older patients and strengthens collaborations between oncologists, geriatricians, and a multidisciplinary team (Box 1). As a result of this conference, the NCI is working to appoint members with expertise in geriatric oncology to its disease-specific steering committee task forces to address these knowledge gaps.
In upcoming U13 grant-supported conferences, we plan to highlight research designs and collaborations that will enhance Box 1. Take-home messages for "Filling the Research Gaps" from the Cancer and Aging Research Group U13 Conference, 2010
